Literature DB >> 16923918

Retroviral E-DNA: persistence and gene expression in nondividing immune cells.

Andrea Cara1, Mary E Klotman.   

Abstract

Following retroviral infection of cells, not only is the proviral DNA integrated into the host genome, but there is also an accumulation of unintegrated extrachromosomal DNA (E-DNA), both linear and circular. Although the integrated DNA is responsible for the production of viral proteins and new viral progeny, the role of E-DNA has remained uncertain. Several reports have shown that E-DNA is transcriptionally active producing both RNA, as well as viral proteins and that circular E-DNA can persist in nondividing cells, raising questions regarding the potential consequences of this reservoir. Furthermore, integrase inhibitors, presently in clinical trials, shifts the balance of proviral DNA to the E-DNA form. This review is focused on recent work in this field with an emphasis on exploring the potential role of E-DNA in both pathogenesis of retroviral infections, especially HIV-1, and as a tool to deliver and express genes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16923918     DOI: 10.1189/jlb.0306151

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  19 in total

Review 1.  Integration-deficient lentiviral vectors: a slow coming of age.

Authors:  Klaus Wanisch; Rafael J Yáñez-Muñoz
Journal:  Mol Ther       Date:  2009-06-02       Impact factor: 11.454

Review 2.  HIV integrase inhibitors: 20-year landmark and challenges.

Authors:  Mathieu Métifiot; Christophe Marchand; Yves Pommier
Journal:  Adv Pharmacol       Date:  2013

3.  An HIV-1 replication pathway utilizing reverse transcription products that fail to integrate.

Authors:  Benjamin Trinité; Eric C Ohlson; Igor Voznesensky; Shashank P Rana; Chi N Chan; Saurabh Mahajan; Jason Alster; Sean A Burke; Dominik Wodarz; David N Levy
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

4.  Transduction of human antigen-presenting cells with integrase-defective lentiviral vector enables functional expansion of primed antigen-specific CD8(+) T cells.

Authors:  Donatella R M Negri; Roberta Bona; Zuleika Michelini; Pasqualina Leone; Iole Macchia; Mary E Klotman; Mirella Salvatore; Andrea Cara
Journal:  Hum Gene Ther       Date:  2010-08       Impact factor: 5.695

5.  Transcription of preintegrated HIV-1 cDNA modulates cell surface expression of major histocompatibility complex class I via Nef.

Authors:  Richard D Sloan; Björn D Kuhl; Daniel A Donahue; André Roland; Tamara Bar-Magen; Mark A Wainberg
Journal:  J Virol       Date:  2011-01-05       Impact factor: 5.103

Review 6.  Molecular mechanisms of HIV-1 persistence in the monocyte-macrophage lineage.

Authors:  Valentin Le Douce; Georges Herbein; Olivier Rohr; Christian Schwartz
Journal:  Retrovirology       Date:  2010-04-09       Impact factor: 4.602

7.  Nonintegrating Lentiviral Vector-Based Vaccine Efficiently Induces Functional and Persistent CD8+ T Cell Responses in Mice.

Authors:  Donatella R M Negri; Zuleika Michelini; Silvia Baroncelli; Massimo Spada; Silvia Vendetti; Roberta Bona; Pasqualina Leone; Mary E Klotman; Andrea Cara
Journal:  J Biomed Biotechnol       Date:  2010-05-19

8.  Expression of Nef from unintegrated HIV-1 DNA downregulates cell surface CXCR4 and CCR5 on T-lymphocytes.

Authors:  Richard D Sloan; Daniel A Donahue; Björn D Kuhl; Tamara Bar-Magen; Mark A Wainberg
Journal:  Retrovirology       Date:  2010-05-13       Impact factor: 4.602

9.  Early onset of autoimmune disease by the retroviral integrase inhibitor raltegravir.

Authors:  Gabriele B Beck-Engeser; Dan Eilat; Thomas Harrer; Hans-Martin Jäck; Matthias Wabl
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-18       Impact factor: 11.205

10.  Novel regulation of HIV-1 replication and pathogenicity: Rev inhibition of integration.

Authors:  Aviad Levin; Zvi Hayouka; Ruth Brack-Werner; David J Volsky; Assaf Friedler; Abraham Loyter
Journal:  Protein Eng Des Sel       Date:  2009-10-29       Impact factor: 1.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.